


AccuDiag™
CA-12-5
ELISA Kit

Cat# 6502-16



Test	CA-12-5 ELISA
Method	Enzyme Linked Immunosorbent Assay
Principle	Sandwich Complex
Detection Range	0-400U/mL
Sample	50µL serum
Specificity	97 %
Sensitivity	5U/ml
Total Time	~ 200 min
Shelf Life	12 Months from the manufacturing date

INTENDED USE

The CA-12-5 EIA test is primarily intended for use as a monitoring and screening test. An abnormal result (i.e., elevated serum CA-12-5 level) can indicate ovarian cancer and suggests the need for further clinical management. The serum CA-12-5 test appears to be a useful tumor marker for patients in clinical remission, following treatment. Post-operative serum CA-12-5 values that fail to return to normal, strongly suggest the presence of residual tumor. Tumor recurrence is often accompanied by a rise of serum CA-12-5 before progressive disease is clinically evident.

SUMMARY AND EXPLANATION

One in every 70 American women will develop ovarian cancer in her life. There are approximately 20,000 new cases of ovarian cancer diagnosed every year and more than 12,000 women die each year because of it. Ovarian cancer is the most malignant type of gynecological cancers, with an overall 5-year survival rate of only 30%. This is because diagnosis is often not made until the advanced stage. Cancer Antigen 125 (CA-12-5) is a surface antigen associated with epithelial ovarian cancer. In serum, CA-12-5 is associated with a high molecular weight glycoprotein. Serum concentrations of this tumor marker can be detected and measured by a murine monoclonal antibody. Published studies have indicated that elevated serum CA-12-5 levels can be found in individuals with serious endometrioid, clear-cell and undifferentiated ovarian carcinoma. Serum

CA-12-5 levels higher than normal can also be found in individuals with adenocarcinoma of the fallopian tube endometrium, certain non-gynecologic malignancies and some non-malignant conditions.

The serum CA-12-5 concentration is greater than 35 units per ml in about 60% of women with ovarian cancer. More than 80% of patients with disseminated

ovarian cancer, have serum CA-12-5 concentrations greater than 35 units per ml. The serum CA-12-5 is elevated in 1% of normal healthy women, 3% of normal healthy women with benign ovarian diseases, 6% of patients with non-neoplastic conditions (including but not limited to first trimester pregnancy, menstruation, endometriosis, uterine fibrosis, acute salpingitis, hepatic diseases and inflammation of peritoneum, pericardium or pleura). Serum levels of CA-12-5 greater than 35 units per ml. combined with pelvic examination increases the test specificity. Serial determinations of serum CA-12-5 further enhances the positive predictive value of the test for ovarian cancer. Serum CA-12-5 concentration may be useful in monitoring patients with diagnosed ovarian cancer. A persistently high serum CA-12-5 may be associated with progressive malignant disease and poor therapeutic response. On the other hand, a declining CA-12-5 value appears to be indicative of a favorable prognosis and a good response to treatment. Residual disease is confirmed in 95% of patients with serum CA-12-5 concentrations greater than 35 units per ml., however, negative results do not necessarily exclude the disease. To date, CA-12-5 is the most sensitive marker for residual epithelial ovarian cancer. CA-12-5 may also be elevated in patients with lung, cervical, fallopian tube, and uterine cancer and endometriosis.

TEST PRINCIPLE

The CA-12-5 Quantitative Test Kit is based on a solid phase enzyme-linked immunosorbent assay. The assay system utilizes one monoclonal anti-CA-12-5 antibody for solid phase (microtiter wells) immobilization and another monoclonal anti-CA 125 antibody in the antibody-enzyme (horseradish peroxidase) conjugate solution. The standards and test specimen (serum) are added to the CA-12-5 antibody coated microtiter wells. Then CA-12-5 antibody labeled with horseradish peroxidase (conjugate) is added. If human CA-12-5 is present in the specimen, it will combine with the antibody on the well and the enzyme conjugate resulting in the CA-12-5 molecules being sandwiched between the solid phase and enzyme-linked antibodies. After a 3 hour incubation at 37°C, the wells are washed with water to remove unbound labeled antibodies. A solution of TMB is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of 2N HCl. The color is changed to yellow and measured spectrophotometrically at 450 nm. The concentration of CA-12-5 is directly proportional to the color intensity of the test sample.

SPECIMEN COLLECTION AND PREPARATION

1. Blood should be drawn using standard venipuncture techniques and the serum should be separated from the red blood cells as soon as practical. Avoid grossly hemolytic, lipemic or turbid samples.
2. Plasma samples collected in tubes containing EDTA, heparin, or oxalate may interfere with test procedures and should be avoided.
3. Specimens should be capped and may be stored up to 48 hours at 2-8°C, prior to assaying. Specimens held for a longer time can be frozen at -20°C. Thawed samples must be mixed prior to testing.

MATERIALS AND COMPONENTS

Materials provided with the test kits

1. Monoclonal anti-CA-12-5 antibody coated microtiter plate with 96 wells.
2. Enzyme conjugate reagent, 12 ml.
3. CA-12-5 reference standards containing; 0, 15, 50, 100, 200, and 400 Unit/ml of CA-12-5, liquid, ready to use 1 set.
4. TMB Substrate, 12 ml
5. Sotp Solution, 12ml.
6. Wash Buffer Concentrate (50X), 15ml.



Materials required but not provided

1. Precision pipettes and tips, 0.04~0.2ml
2. Disposable pipette tips.
3. Distilled water.
4. Vortex mixer.
5. Absorbent paper or paper towel.
6. Microtiter plate reader.
7. Graph paper.

REAGENT PREPARATION

1. All reagents should be brought to room temperature (18-22°C) and mixed by gently inverting or swirling prior to use. Do NOT induce foaming.
2. Dilute 1 volume of Wash Buffer (50x) with 49 volumes of distilled water. For example, Dilute 15 ml of Wash Buffer (50x) into distilled water to prepare 750 ml of washing buffer (1x). Mix well before use

ASSAY PROCEDURE

1. Secure the desired number of coated wells in the holder. Dispense 50µl of CA 125 standards, specimens, and controls into the appropriate wells. Gently but thoroughly mix for 10 seconds.
2. Dispense 100µl of enzyme conjugate reagent into each well. Mix gently for 30 seconds. It is very important to have complete mixing in this setup. Incubate at 37°C for 3 hours.
3. Remove the incubation mixture by emptying the plate content into a waste container. Rinse and empty the microtiter plate 5 times with washing buffer (1X). Strike the microtiter plate sharply onto absorbent paper or paper towels to remove all residual water droplets.
4. Dispense 100µl of TMB substrate reagent into each well. Gently mix for 10 seconds. Incubate at room temperature, in the dark, for 20 minutes.
5. Stop the reaction by adding 100µl of Stop Solution to each well. Gently mix For 10 seconds until the blue color completely changes to yellow.
6. Read the optical density at 450nm with a microtiter plate reader within 15 minutes.

Important Note:

1. The wash procedure is critical. Insufficient washing will result in poor precision and falsely elevated absorbance readings.
2. It is recommended that no more than 32 wells be used for each assay run if manual pipetting is used since pipetting of all standards, specimens and controls should be completed within 5 minutes. A full plate of 96 wells may be used if automated pipetting is available.
3. Duplication of all standards and specimens, although not required, is recommended.

RESULTS


Calculate the mean absorbance value for each set of CA-12-5 reference standards, specimens and controls. Construct a standard curve by plotting the mean absorbance obtained from each reference standard against its concentration in units per ml on linear graph paper, with absorbance values on the vertical or Y axis and concentrations on the horizontal or X axis. Use the mean absorbance values for each specimen to determine the corresponding concentration of CA-12-5 in units per ml from the standard curve. Any diluted specimens must be corrected by the appropriate dilution factor.

Example of standard curve

Results of a typical standard run with optical density reading at 450nm shown in the Y axis against CA-12-5 concentrations shown in the X axis.

CA-12-5 Values (U/ml)	Absorbance (450nm)
0	0.010
15	0.105
50	0.347
100	0.703
200	1.411
400	2.437

This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each user should obtain his or her own standard curve and data.



Expected values and sensitivity

Healthy women are expected to have CA-12-5 assay values below 35 U/ml. The minimum detectable concentration of CA-12-5 in this assay is estimated to be 5 U/ml.

PERFORMANCE CHARACTERISTICS

I. Accuracy: Comparison between Our Assay and Commercial Available Kits provides the following data

N = 62
 Correlation Coefficient = 0.981
 Slope = 0.933
 Intercept = 2.06
 Mean (Our Kits) = 38.79
 Mean (Abbott) = 35.88

II. Precision.

1]. Intra-Assay:

Concentrations	N	Mean	S.D.	% CV
Level I	20	16.27	0.970	5.96
Level II	20	86.26	4.290	4.97

2]. Inter-Assay

Concentrations	N	Mean	S.D.	% CV
Level I	10	17.19	1.698	9.87
Level II	10	88.62	6.160	6.95

III. Linearity

Two patient sera were serially diluted with 0 U/mL standard in a linearity study. The average recovery was 99.0 %.

Sample A			
Dilution	Expected	Observed	% Recov.
undiluted	218.02	218.02	
2x	109.01	110.62	101.5
4x	54.51	53.02	97.3
8x	27.25	26.11	95.8
16x	13.63	14.80	108.6
Average Recovery: 100.8 %			

Sample B			
Dilution	Expected	Observed	% Recov.
undiluted	260.33	260.33	
2x	130.17	128.23	98.5
4x	65.08	64.98	99.8
8x	32.54	31.76	97.6
16x	16.27	15.11	92.9
Average Recovery: 97.2 %			

IV. Sensitivity

The sensitivity is defined as the concentration of CA-12-5 that corresponds to the absorbance that is two standard deviations greater than the mean absorbance of 20 replicates of the zero calibrator. The minimum detectable concentration of this assay is estimated to be 5.0 U/mL.

V. Cross-reactivity

The following cancer marker antigens at high concentrations, as seen in cancer patients, were assayed to determine the possible reactivity.

Antigens	Concentration	Equivalent CA-12-5	% Cross-reactivity
CA 15-3	1,000 U/mL	0.00	0.00
CA 19-9	1,000 U/mL	0.00	0.00
PSA	1,000 ng/mL	0.00	0.00
PAP	1,000 ng/mL	0.00	0.00
AFP	10,000 ng/mL	0.00	0.00
CEA	1,000 ng/mL	0.00	0.00

VII. Hook Effect

No hook effect at concentrations as high as 5,000 U/mL.

LIMITATIONS OF THE PROCEDURE

- Reliable and reproducible results will be obtained when the assay procedure is carried out with a complete understanding of the package insert instructions and with adherence to good laboratory practice.
- The wash procedure is critical. Insufficient washing will result in poor precision and falsely elevated absorbance readings.
- Heterophilic antibodies such as human anti-mouse antibodies (HAMA) are frequently found in the serum of human subjects. Those antibodies can cause severe interference in many immunodiagnostic procedures. This assay has been designed to minimize that kinds of interference. Nevertheless, complete elimination of this interference from all patient specimens cannot be guaranteed. A test result that is inconsistent with the clinical picture and patient history should be interpreted with caution.


STORAGE


- Unopened test kits should be stored at 2-8°C upon receipt and the microtiter plate should be kept in a sealed bag with desiccants to minimize exposure to damp air. The test kit may be used throughout the expiration date of the kit (One year from the date of manufacture). Refer to the package label for the expiration date.
- Opened test kits will remain stable until the expiring date shown, provided it is stored as prescribed above.
- A microtiter plate reader with a bandwidth of 10nm or less and an optical density range of 0-2 OD or greater at 450nm wavelength is acceptable for use in absorbance measurement.

REFERENCES

- Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. Ca125 in gynecological pathology a review. *Eur J Obstet Gynecol* 1993;49:115-124.
- Saksela F. Prognostic markers in epithelial ovarian cancer. *Intl J Gynecol Pathol* 1993;12:156-161.
- Farghaly SA. Tumor markers in gynecologic cancer. *Gynecol & Obstet Invest* 1992;34:65-72.
- Welander CE. What do CA 125 and other antigens tell us about ovarian cancer biology. *Acta Obstet Gynecol Scand Sup* 1992;155:85-93.
- McGowan L. Pathology of the ovary. *Curr Opin on Obstet Gynecol* 1991;3:580-586.
- Niloff JM. Ovarian malignancy. *Curr Opin on Obstet Gynecol* 1991;3:66-72.
- Olt G, Berchuck A, Bast RC. The role of tumor markers in gynecologic oncology. *Obstet Gynecol Survey* 1990;45:-570-577.
- Diez M, Cerdan FJ, Ortega MD, Torres A, Picardo A, Balibrea JL. Evaluation of serum CA-12-5 as a tumor marker in non-small cell lung cancer. *Cancer* 1991;67:150-154.
- Niloff JM, Klug TL, Schaeztl E. Elevation of serum CA-12-5 in carcinomas of the fallopian tube, endometrium, and endocervix. *AM J. Obstet Gynecol* 1984; 148:1057.

ISO 13485
ISO 9001



 **Diagnostic Automation/
Cortez Diagnostics, Inc.**

**21250 Califa Street, Suite 102 and 116,
Woodland Hills, California 91367 USA**

Date Adopted	Cat # 6502-16
2012-06-01	AccuDiag™- CA-12-5 ELISA-2015
<div style="border: 1px solid black; display: inline-block; padding: 2px;">EC</div> <div style="border: 1px solid black; display: inline-block; padding: 2px; margin-left: 10px;">REP</div>	
CEpartner4U, Esdoornlaan 13, 3951DB Maarn. The Netherlands. www.cepartner4u.eu	
Revision D Date 2015-09-14	